Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 1, 1976, and listed on October 26, 2020 [2] - The company primarily engages in the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [2] - The revenue composition is as follows: Inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine chemicals 7.46%, and other products 4.28% [2] Stock Performance - As of September 4, the stock price of Dayang Biological fell by 2.21% to 34.90 CNY per share, with a market capitalization of 2.932 billion CNY [1] - Year-to-date, the stock price has increased by 90.46%, with a 5-day increase of 8.59%, a 20-day increase of 10.72%, and a 60-day increase of 41.07% [2] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on June 16 [2] Financial Performance - For the first half of 2025, Dayang Biological achieved a revenue of 499 million CNY, representing a year-on-year growth of 14.20% [2] - The net profit attributable to the parent company was 50.51 million CNY, showing a year-on-year increase of 60.66% [2] - Cumulative cash dividends since the A-share listing amount to 168 million CNY, with 97.57 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders increased to 14,200, a rise of 58.33% from the previous period [2] - The average number of tradable shares per shareholder decreased by 35.82% to 4,954 shares [2] Market Position - Dayang Biological is classified under the Shenwan industry category of basic chemicals - chemical raw materials - inorganic salts [2] - The company is associated with several concept sectors, including raw materials, synthetic biology, fluorine chemicals, share buybacks, and small-cap stocks [2]

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本公告日前十二个月公司使用闲置募集资金进行现金管理的情况 截至本公告日，公司及子公司使用闲置募集资金进行现金管理尚未到期的金 额为人民币 11,000.00 万元，未超出公司第六届董事会第五次会议关于使用闲置募 集资金进行现金管理的授权额度。截至本公告日，公司使用闲置募集资金进行现 金管理具体情况如下： | | | | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 申 | 签 | | | | 产 | | 起 | | 到 | | | 是 | | 序 | 购 | 约 | | | | 品 | 认购金 | | 息 | | 期 | 预期年化 | | | 收 | | | 否 | 投资 | | | | | | | | | | | | ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2025 年 8 月 22 日召开第六届董事会第五次会议、第六届监事会第 五次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议案》。 根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响募投项 目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下简称"福 建舜跃"）使用最高额度不超过 12,000.00 万元（含本数）闲置募集资金进行现金 管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月之内有效。具 体内容详见公司在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于继续使用部分闲置募集资金进行 ...

证券之星消息，9月1日化学原料板块较上一交易日上涨0.86%，大洋生物领涨。当日上证指数报收于 3875.53，上涨0.46%。深证成指报收于12828.95，上涨1.05%。化学原料板块个股涨跌见下表： 从资金流向上来看，当日化学原料板块主力资金净流出1.08亿元，游资资金净流入2.21亿元，散户资金净 流出1.13亿元。化学原料板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000830 鲁西化工 | | 7693.36万 | 8.51% | 2740.84万 | 3.03% | -1.04亿 | -11.54% | | 003017 | 大洋生物 | 5691.53万 | 10.59% | -5760.58万 | -10.72% | 69.06万 | 0.13% | | 002145 | 中核钛白 | 4507.41万 | 4.34% | 302.27万 | 4 0.29% | -- ...

Core Viewpoint - Zhejiang Dayang Biological Technology Group Co., Ltd. announced a share reduction plan by its actual controllers and their concerted actors, which involves a total reduction of up to 839,123 shares, accounting for 1.00% of the company's total share capital [1][2][3]. Summary by Sections Shareholders' Information - The total number of shares held by the concerted actors is 2,140,518 shares, representing 2.56% of the company's total share capital [2]. - Individual holdings include: - Mr. Hao Bingyan: 1,123,595 shares (1.34%) - Mr. Qian Jianchun: 770,000 shares (0.92%) - Mr. Chen Shouliang: 199,123 shares (0.24%) - Ms. Zhao Yumei: 47,800 shares (0.06%) [1]. Reduction Plan Details - The share reduction will occur within three months following the announcement, excluding periods when reductions are prohibited by the Shenzhen Stock Exchange [1][3]. - The shares to be reduced are from those acquired before the company's IPO and through capital reserve conversion [2][3]. Compliance and Commitments - The shareholders have committed to not transferring or entrusting their shares for 36 months post-IPO, with specific conditions for any subsequent reductions [4]. - The shareholders have adhered to their commitments without any violations of regulations or agreements [4][5]. Impact on Company Governance - The planned share reduction will not lead to a change in control of the company and is not expected to significantly impact the company's governance structure or ongoing operations [5].

截至发稿，大洋生物市值为27亿元。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 （记者 王晓波） 每经AI快讯，大洋生物（SZ 003017，收盘价：32.14元）8月28日晚间发布公告称，公司于近日收到实 际控制人的一致行动人郝炳炎先生、钱建春先生、陈寿良先生、赵玉梅女士出具的《关于股份减持计划 的事先告知函》，浙江大洋生物科技集团股份有限公司实际控制人的一致行动人郝炳炎先生、钱建春先 生、陈寿良先生、赵玉梅女士拟自本次股份减持计划预披露公告披露之日起15个交易日后的连续三个月 内以集中竞价交易方式减持公司股份合计不超约84万股（含本数），不超过公司总股本的1%。 截至本公告披露日，郝炳炎先生持有公司股份总数约为112万股，占公司总股本的比例为1.34%；钱建 春先生持有公司股份总数为77万股，占公司总股本的比例为0.92%；陈寿良先生持有公司股份总数约为 20万股，占公司总股本的比例为0.24%；赵玉梅女士持有公司股份总数约为4.78万股，占公司总股本的 比例为0.06%。 2025年1至6月份，大洋生物的营业收入构成 ...

证券代码：003017 证券简称：大洋生物 公告编号：2025-084 浙江大洋生物科技集团股份有限公司 关于实际控制人的一致行动人减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本次减持计划的具体安排 1.减持原因：股东自身资金需求。 浙江大洋生物科技集团股份有限公司（以下简称"公司"或"本公司"）实 际控制人的一致行动人郝炳炎先生、钱建春先生、陈寿良先生、赵玉梅女士拟自 本次股份减持计划预披露公告披露之日起 15 个交易日后的连续三个月内（即自 2025 年 9 月 19 日起至 2025 年 12 月 18 日止，根据中国证券监督管理委员会或 深圳证券交易所相关规定禁止减持的期间除外）以集中竞价交易方式减持公司股 份合计不超 839,123 股（含本数），不超过公司总股本的 1.00%。 截至本公告披露日，郝炳炎先生持有本公司股份总数为 1,123,595 股，占公 司总股本的比例为 1.34%；钱建春先生持有本公司股份总数为 770,000 股，占公 司总股本的比例为 0.92%；陈寿良先生持有本公司股份总数为 199,123 ...

Core Insights - The company achieved double-digit growth in both revenue and net profit during the first half of 2025, despite a challenging global economic environment and fluctuations in raw material prices [1][2] - The "one body, two wings" industrial structure has proven effective, with significant contributions from various business segments [2][3] Financial Performance - The company reported a revenue of 499 million yuan, representing a year-on-year increase of 14.20% [1] - Net profit attributable to shareholders reached 50.51 million yuan, up 60.66% year-on-year, with a net profit margin improvement [1] - The net profit after deducting non-recurring gains and losses was 46.76 million yuan, reflecting a growth rate of 60.74% [1] Business Operations - The inorganic salt product segment (potassium carbonate/potassium bicarbonate) generated 349 million yuan in revenue, a year-on-year increase of 11.48%, with a gross margin of 20.42% [2] - The veterinary raw material drug segment, particularly the hydrochloride of amprolium, saw revenue of 91.62 million yuan, a significant increase of 66.56% [2] - The fluorine-containing fine chemicals segment experienced a revenue decline of 5.25% to 37.24 million yuan, although gross margin improved to 24.83% [2] Research and Development - The company holds 51 valid invention patents and 21 utility model patents, and has participated in drafting multiple national and industry standards [3] - The company has developed an ion exchange closed-loop system that achieves zero discharge of ammonia nitrogen wastewater, establishing a competitive edge in environmental protection [3] Future Outlook - The company plans to continue focusing on high value-added product development and market expansion domestically, while enhancing its competitive advantages in international markets [3] - Ongoing projects and technological innovations are expected to support revenue growth in the inorganic salt, veterinary raw materials, and fluorine-containing fine chemicals sectors [3]

公司最新毛利率为24.31%，在已披露的同业公司中排名第10，较上季度毛利率增加1.15个百分点，实现4个季度连续上涨，较去年同期毛利率增加5.28个百 分点，实现3年连续上涨。最新ROE为4.67%，在已披露的同业公司中排名第11，较去年同期ROE增加1.56个百分点。 公司摊薄每股收益为0.62元，在已披露的同业公司中排名第3，较去年同报告期摊薄每股收益增加0.24元，同比较去年同期上涨61.06%。 2025年8月26日，大洋生物(003017.SZ)发布2025年中报。 公司营业总收入为4.99亿元，较去年同报告期营业总收入增加6209.19万元，同比较去年同期上涨14.20%。归母净利润为5050.56万元，在已披露的同业公司 中排名第17，较去年同报告期归母净利润增加1906.92万元，实现2年连续上涨，同比较去年同期上涨60.66%。经营活动现金净流入为1.13亿元，较去年同报 告期经营活动现金净流入增加7962.10万元，同比较去年同期上涨235.94%。 公司最新资产负债率为33.55%，在已披露的同业公司中排名第14，较上季度资产负债率减少1.03个百分点，较去年同期资产负债率减少3.49 ...

公司在不影响正常运营前提下，使用部分闲置自有资金购买理财产品，不会影响日常经营。适度理财可 提高资金使用效率，获得投资收益，为股东谋取更多回报。 2025年8月26日，浙江大洋生物科技集团股份有限公司（证券代码：003017，以下简称"大洋生物"）发 布了关于继续使用闲置自有资金进行现金管理的公告。公司于2025年8月22日召开第六届董事会第五次 会议和第六届监事会第五次会议，同意公司（含子公司）使用不超过30,000.00万元（含本数）的闲置自 有资金进行现金管理。 现金管理基本情况购买理财产品品种：为控制风险，公司所购理财产品为安全性高、流动性好、风险可 控、稳健的产品，不涉及《深圳证券交易所上市公司自律监管指引第1号 - 主板上市公司规范运作》中 的风险投资品种，如股票及其衍生品投资、基金投资、期货投资、房地产投资等。现金管理额度：拟使 用不超过30,000.00万元（含本数）的闲置自有资金，在董事会决议有效期内可滚动使用。投资期限：自 董事会审议通过之日起12个月内有效。资金来源：为公司暂时闲置自有资金，公司将合理预算和安排资 金收支，确保不影响日常生产经营。具体实施方式：提请董事会授权总经理在额度范 ...